39 completed, 3 terminated, 1 active not recruiting, 1 withdrawn. 32 Phase 2, 16 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 32 | Completed 28, Terminated 3, Active not recruiting 1 |
| Phase 1 | 16 | Completed 15, Withdrawn 1 |
Follow cixutumumab: new trials by email Literature Review of cixutumumab trials Research Report on cixutumumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus - Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 46 | 2012-06-18 | 2018-12-11 |
| Preoperative Treatment With Cetuximab and/or IMC-A12 Cetuximab, IMC-A12, Surgical tumor resection - Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 16 | 2011-10-17 | 2020-03-19 |
| Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye Cixutumumab, Laboratory biomarker analysis - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2011-08-01 | 2020-02-19 |
| BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer Carboplatin, Pemetrexed, Bevacizumab - Lung Cancer | Phase 2 | Completed | M.D. Anderson Cancer Center | 64 | 2011-05-17 | 2019-05-15 |
| A Study in Non-Small Cell Lung Cancer Pemetrexed, Cisplatin, Cixutumumab - Non-Small-Cell Lung Carcinoma | Phase 2 | Completed | Eli Lilly and Company | 172 | 2011-04-01 | 2019-09-20 |
| Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer Bicalutamide, Cixutumumab, Goserelin Acetate - Prostate Adenocarcinoma, Recurrent Prostate Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 211 | 2010-12-01 | 2018-02-26 |
| Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Cixutumumab, Everolimus, Laboratory Biomarker Analysis - Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 27 | 2010-10-01 | 2016-07-15 |
| Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Cixutumumab, Laboratory Biomarker Analysis, Paclitaxel - Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 94 | 2010-09-21 | 2026-09-10 |
| A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors IMC-A12, Temsirolimus - Brain Stem Neoplasms, Glioma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2010-07-28 | 2017-07-02 | |
| Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy IMC-A12 - Pleural Mesothelioma, Peritoneal Mesothelioma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2010-06-02 | 2018-04-10 |
| Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer Bevacizumab, Carboplatin, Cixutumumab - Large Cell Lung Carcinoma, Lung Adenocarcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 175 | 2010-03-01 | 2018-06-06 |
| Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma Cixutumumab, Cyclophosphamide, Dactinomycin - Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 175 | 2010-01-01 | 2017-08-29 |
| Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies Cixutumumab, Laboratory Biomarker Analysis, Pharmacological Study - Adult Solid Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2009-11-01 | 2016-01-25 |
| A Study of IMC-A12 in Advanced Solid Tumors Cixutumumab - Tumors | Phase 1 | Completed | Eli Lilly and Company | 21 | 2009-11-01 | 2019-02-27 |
| Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus - Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 178 | 2009-11-01 | 2015-07-30 |
| Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer Cixutumumab, Diagnostic Laboratory Biomarker Analysis, Temsirolimus - Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 16 | 2009-10-01 | 2019-06-17 |
| A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer BIIB022 With Paclitaxel and Carboplatin - Non-Small Cell Lung Cancer | Phase 1 | Completed | Biogen | 18 | 2009-10-01 | 2013-09-16 |
| Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer cixutumumab, carboplatin, paclitaxel - Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 140 | 2009-09-01 | 2014-09-26 |
| Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer Cixutumumab, Laboratory Biomarker Analysis, Sorafenib Tosylate - Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 21 | 2009-08-01 | 2016-05-12 |
| A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Cisplatin, Cixutumumab, Etoposide - Extensive Stage Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 168 | 2009-07-16 | 2026-06-24 |
Showing 20 of 44. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (7) · Neoplasms (7) · Sarcoma (6) · Prostatic Neoplasms (5) · Rhabdomyosarcoma (5) · Breast Neoplasms (3) · Carcinoma, Hepatocellular (3) · Neuroectodermal Tumors, Primitive, Peripheral (3) · Osteosarcoma (3) · Sarcoma, Synovial (3) · Adrenocortical Carcinoma (2) · Colorectal Neoplasms (2) · Fibrosarcoma (2) · Head and Neck Neoplasms (2) · Hemangiosarcoma (2)
National Cancer Institute (NCI) (26) · Eli Lilly and Company (14) · M.D. Anderson Cancer Center (2) · Biogen (1) · University of Washington (1)
United States (42) · Canada (7) · Australia (2) · Belgium (2) · France (2) · Germany (2) · Netherlands (2) · Spain (2) · Argentina (1) · Brazil (1) · Israel (1) · Italy (1) · Japan (1) · New Zealand (1) · Poland (1)
Aung Naing (1) · Brenda Weigel, MD (1) · Bruce Montgomery, M.D. (1) · Chandra Belani (1) · Cynthia Ma (1) · Dana Rathkopf (1) · David Camidge (1) · Dennis D Hickstein, M.D. (1) · Evan Yu (1) · Gary Hammer (1) · George Simon, MD (1) · Ghassan Abou-Alfa (1)
PMID 25749986, PMID 22682017, PMID 23477833, PMID 23533230, PMID 24668327, PMID 25847934, PMID 25858498, PMID 25900182, PMID 26082390, PMID 27139036, PMID 28950351, PMID 33852121, PMID 37104870
N01CM00071 (4), U10CA021115 (4), N01CM00038 (3), P30CA008748 (3), P30CA016672 (3), U10CA098543 (3), U10CA180820 (3), N01CM00099 (2), N01CM00100 (2), N01CM62201 (2), N01CM62205 (2), N01CM62207 (2), N01CM62209 (2), U01CA062461 (2), U01CA097452 (2)